Michelino De Laurentiis
Overview
Explore the profile of Michelino De Laurentiis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
4153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, et al.
Eur J Cancer
. 2024 Nov;
213():115113.
PMID: 39536433
Purpose: The aim of this study was to evaluate the effectiveness of CDK 4/6 inhibitors (CDK 4-6i) according to HER2 status (low/zero), and endocrine resistance/sensitivity, as well as the efficacy...
12.
Bardia A, Jhaveri K, Im S, Pernas S, De Laurentiis M, Wang S, et al.
J Clin Oncol
. 2024 Sep;
43(3):285-296.
PMID: 39265124
Purpose: The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in hormone receptor-positive/human...
13.
Pagliuca M, Havas J, Thomas E, Drouet Y, Soldato D, Franzoi M, et al.
J Natl Cancer Inst
. 2024 Sep;
117(1):89-102.
PMID: 39250750
Background: Fatigue, cognitive impairment, anxiety, depression, and sleep disturbance are cancer-related behavioral symptoms that may persist years after early-stage breast cancer, affecting quality of life. We aimed to generate a...
14.
Zambelli A, Cortesi L, Gaudio M, Arpino G, Bianchini G, Caruso F, et al.
Cancer Treat Rev
. 2024 Aug;
130:102815.
PMID: 39208751
The introduction of PARP inhibitors has revolutionized the management and treatment of patients with pathogenic germline variants of BRCA1/2 who have developed breast cancer. The implementation of PARP inhibitors in...
15.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Aug;
10(1):68.
PMID: 39095493
No abstract available.
16.
Hamilton E, Ma C, De Laurentiis M, Iwata H, Hurvitz S, Wander S, et al.
Future Oncol
. 2024 Jul;
20(32):2447-2455.
PMID: 39072356
Vepdegestrant (ARV-471) is an oral PROTAC ER degrader that binds an E3 ubiquitin ligase and ER to directly trigger ubiquitination of ER and its subsequent proteasomal degradation. In a first-in-human...
17.
Porciello G, Coluccia S, Vitale S, Palumbo E, Luongo A, Grimaldi M, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061215
Health-related quality of life (HRQoL) represents one of the most concerning aspects for cancer patients. The Healthy Eating Index (HEI) is an a priori diet quality index directly associated with...
18.
Caminiti C, Maglietta G, Arenare L, Di Liello R, Migliaccio G, Barberio D, et al.
Breast
. 2024 Jul;
77:103781.
PMID: 39059033
Patients' self-reporting is increasingly considered essential to measure quality-of-life and treatment-related side-effects. However, if multiple patient-reported instruments are used, redundancy may represent an overload for patients. Patient-Reported Outcomes Common Terminology...
19.
Tinterri C, Gentile D, Caruso F, Cortesi L, De Laurentiis M, Fortunato L, et al.
Curr Oncol
. 2024 Jul;
31(7):3815-3825.
PMID: 39057154
Background: Breast units (BUs) provide breast cancer (BC) care, including prevention, treatment, and genetic assessment. Genetic research has highlighted BRCA1/2 mutations as key hereditary BC risk factors. BRCA testing is...
20.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):58.
PMID: 39019916
Abemaciclib demonstrated clinical benefit in women affected by HR+/HER2- advanced breast cancer (aBC). Drug-drug interactions (DDIs) can lead to reduced treatment efficacy or increased toxicity. This retro-prospective study aimed to...